PCN28 COST-UTILITY ANALYSIS IN A SPANISH SETTING OF ADJUVANT THERAPY WITH TRASTUZUMAB (HERCEPTIN®) IN PATIENTS WITH HER-2 POSITIVE BREAST CANCER